Skip to main content
Funded Studies

Amy Ripka, PhD

CEO at Lucy Therapeutics

Location: Cambridge, MA United States

Amy Ripka is CEO of Lucy Therapeutics, a Boston-based, biotech company focused on developing revolutionizing treatments that boost mitochondrial function in neurological diseases. Prior to her role at LucyTx, she held positions of scientific leadership at SAI Life Sciences, WuXiAppTec, EnVivo(FORUM), Daiamed and Infinity Pharmaceuticals. She received her PhD in organic chemistry from the University of Wisconsin-Madison and subsequently worked in the lab of Nobel Laureate K. Barry Sharpless. She has over 30 issued patents and has participated in 6 INDs in different therapeutic areas. She has been a leader in the medicinal chemistry community as Chair of the 2012 Medicinal Chemistry Gordon Research Conference, Industrial Councilor for the ACS MEDI Executive Committee and a SAB member for ADDF, Carraway Therapeutics, and Q-Biomed. She also plays classical violin professionally and has performed with such artists as Yo-Yo Ma, Peter Gabriel, Sarah McLachlan and Smokey Robinson.

Associated Grants

  • (SUPPLEMENT) Small Molecule Mitochondrial Modulators for the Treatment of Parkinson's Disease


  • Using Small Molecules that Modulate Mitochondrial Function for the Treatment of Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.